Selected article for: "antiviral treatment drug development and treatment drug development"
Author: Liu, Xiao-huan; Zhang, Xiao; Lu, Zhen-hua; Zhu, You Shuang; Wang, Tao
Title: Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection
  • Cord-id: qkn5dl6t
  • Document date: 2020_11_17
    • ID: qkn5dl6t
    Snippet: Outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 have produced high pathogenicity and mortality rates in human populations. However, to meet the increasing demand for treatment of these pathogenic coronaviruses, accelerating novel antiviral drug development as much as possible has become a public concern. Target-based drug development may be a promising approach to achieve this goal. In this review, the
    Document: Outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 have produced high pathogenicity and mortality rates in human populations. However, to meet the increasing demand for treatment of these pathogenic coronaviruses, accelerating novel antiviral drug development as much as possible has become a public concern. Target-based drug development may be a promising approach to achieve this goal. In this review, the relevant features of potential molecular targets in human coronaviruses (HCoVs) are highlighted, including the viral protease, RNA-dependent RNA polymerase, and methyltransferases. Additionally, recent advances in the development of antivirals based on these targets are summarized. This review is expected to provide new insights and potential strategies for the development of novel antiviral drugs to treat SARS-CoV-2 infection.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and adp ribose: 1, 2
    • action mechanism and adp ribosylation: 1
    • activate factor and adp ribosylation: 1
    • active cov and adenosine prodrug: 1, 2
    • active cov and adp ribose: 1
    • active site and adp ribose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • active triphosphate and adenosine prodrug: 1, 2, 3, 4, 5, 6
    • activity broad spectrum and adenosine prodrug: 1, 2, 3, 4